Tirzepatide produced significant weight loss, reduced insulin requirements, and improved glucose control without increasing hypoglycemia when used off-label in adults with type 1 diabetes (T1D), new ...

GLP-1 receptor agonist or SGLT2 inhibitor prescribing became more common for people with type 1 diabetes in recent years, a nationwide cross-sectional analysis found. From 2010 to 2023, the percentage ...

Zimislecel is an allogeneic stem cell–derived islet-cell therapy. Data on the safety and efficacy of zimislecel in persons with type 1 diabetes are needed. We conducted a phase 1–2 study of zimislecel ...

The effects of the JAK inhibitor baricitinib (Olumiant) waned after treatment was stopped among patients with new-onset type 1 diabetes, 2-year data from the phase II BANDIT trial showed. After ...

A daily pill previously shown to slow the progression of type 1 diabetes has now shown a loss of therapeutic benefit when stopped—affirming the promise of the treatment. In 2023, an Australian trial ...